Loading quotes...

Forecast

The analysts' average price target is €39.23 (+52.05%). The median is €39.35 (+52.52%).

Buy	25
Hold	2
Sell	1

News Go to news feed

Xencor: positive Phase‑1 data on XmAb819 spark 15% share surge

Clinical dose‑selection data for the kidney cancer candidate XmAb819 convinced investors and led to an about 15% rise in the share price. The company plans to start a potentially approval‑relevant study by the end of 2027. Available cash secures operations until at least 2029 and supports a revaluation of the biotech platform. » More on finanzen.net
Xencor shifts strategy to late-stage development focusing on XmAb819

At the Cantor Fitzgerald Healthcare Conference Xencor presented its transition from a platform licensor to a late-stage clinical developer and is concentrating on its in-house XmAb portfolio. Lead program XmAb819 for renal cell carcinoma showed an early objective response rate of 25%; an ESMO update in about a month should clarify dose selection and response duration and pave the way for a registration-relevant study in 2025. The company is stopping monotherapy development of XmAb541 in favor of combinatorial “AND-gate” approaches and is also advancing TL1A programs as well as partner projects with Astellas and Johnson & Johnson. » More on de.investing.com
Xencor hits 52-week high at $21.99

Xencor’s stock climbed to a 52-week high of $21.99 and is currently trading at $21.89, with an annual performance of +41% and a one-year gain of 178.71%. Five analysts have recently raised their earnings estimates, although the stock is trading above their fair‑value estimates. In addition, the phase-1 study of the bispecific antibody XmAb819 was accepted for presentation at the ESMO Congress (Oct. 23–27, 2026), with a focus on advanced clear‑cell renal cell carcinoma. » More on de.investing.com

Financials

In the last quarter, Xencor had revenue of €44.88M and net profit of -€19.04M

(EUR)	June 2026	YoY
Revenue	44.88M	21.31%
Gross profit	44.88M	29.16%
Net profit	-19.04M	27.20%
EBITDA	-10.63M	37.93%

Fundamentals

Metric	Value
Market capitalization	€1.99B
Number of shares	74.35M
52-week high/low	€30.05 - €9.28
Dividends	No
Beta	0.90
P/E ratio	-13.82
PEG ratio	0.19
P/B ratio	4.52
P/S ratio	21.24

Company profile

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. In addition, it is developing VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. Further, the company is developing AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.